news
Proteomics: dynamics of iron-sulphur cluster binding
Proteomic platform developed by US scientists affords a greater insight into the dynamics of iron-sulphur clusters delivery and binding.
List view / Grid view
Omics
whitepaper
Whitepaper: Cell cycle and DNA damage and repair
Explore pathways of cell cycle control, revealing mechanisms of cell cycle arrest, DNA damage and senescence using this ebook.
news
The future for quality control of mRNA medications
Japanese researchers combine cutting edge mass spectrometry with software analysis to elucidate mRNA structure.
article
Understanding molecular mechanisms behind breast cancer
Oestrogen receptors play a crucial role in breast cancer. By making them therapeutic targets, oestrogen can be regulated with the aim to prevent breast cancer.
news
What do cancer cells crave?
US researchers uncover the amino acid: arginine, that prompts genetic mutations in cancer cells.
whitepaper
Whitepaper: Oncology therapeutics discovery solutions
Streamline oncology therapeutic development with CST® recombinant monoclonal antibodies, ELISA & cellular assay kits, & custom products & services.
article
Developing state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
news
Discovery of novel mechanism for MRSA virulence
US researchers revealed that MRSA has undergone repeated mutations in the sarZ gene, leading to increased severity of blood stream infections in mouse models.
article
Allogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
news
Researchers develop novel method to insert large DNA sequences more accurately in cells
The scientists say that the engineered CRISPR enzymes could overcome key limitations for eventual use to treat genetic diseases irrespective of a patient’s particular mutation.
article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
whitepaper
Whitepaper: Neurodegeneration therapeutics discovery
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.
article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
news
A change in genetic code causes lung cancer to develop
Using lung basal cell organoids, researchers identify a gene that directs the development of lung cancer and offers a better understanding of its disease treatment.
whitepaper
Poster: Antibodies for microglial activation states
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.